UNDERSTANDING METHOTREXATE CONCENTRATIONS AND ASSOCIATED TOXICITIES TO GUIDE SUPPORTIVE CARE IN PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL)

被引：0
|
作者：
Taylor, Z. [1 ]
Miller, T. [2 ]
DeGroote, N. [3 ]
Pommert, L. [1 ]
Awoniyi, O. [3 ]
Board, S. [1 ]
Poweleit, E. [1 ]
Ugboh, N. [2 ]
Joshi, V. [3 ]
Ambrosino, N. [1 ]
Chavana, A. [4 ]
Bernhardt, M. [4 ]
Schafer, E. [4 ]
O'Brien, M. [1 ]
Castellino, S. [3 ]
Ramsey, L. [1 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
[2] Emory Univ, Atlanta, GA USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Baylor Coll Med, Houston, TX USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-044
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [41] Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma
    Uluoglu, C
    Oguz, A
    Timlioglu, Ö
    Biberoglu, G
    Hasanoglu, A
    GENERAL PHARMACOLOGY, 1999, 32 (02): : 215 - 218
  • [42] HIV-associated Non-Hodgkin lymphoma in 114 patients with undetectable HIV viral load at NHL diagnosis
    Oksenhendler, Eric
    Gerard, Laurence
    Galicier, Lionel
    Leturque, Nicolas
    Janin, Anne
    Meignin, Veronique
    BLOOD, 2007, 110 (11) : 471A - 471A
  • [43] Classification of Non-Hodgkin Lymphoma (NHL) in the Developing World: The International NHL Classification Project
    Perry, Anamarija
    Diebold, Jacques
    MacLennan, Kenneth
    Muller-Hermelink, H. Konrad
    Nathwani, Bharat N.
    Boilesen, Eugene
    Bast, Martin
    Armitage, James
    Weisenburger, Dennis D.
    LABORATORY INVESTIGATION, 2016, 96 : 368A - 368A
  • [44] Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma
    Uchida, Mayako
    Mori, Yasuhiro
    Akiba, Kenta
    Miyasaka, Moena
    Hirano, Tatsuya
    Ikesue, Hiroaki
    Yamaguchi, Yuki
    Takano, Aoi
    Maegawa, Nami
    Shimomura, Yoshimitsu
    Hosohata, Keiko
    Muroi, Nobuyuki
    Ishikawa, Takayuki
    Hashida, Tohru
    Nakamura, Tsutomu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2020, 43 (10) : 1577 - 1582
  • [45] Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-hodgkin's lymphoma (NHL).
    Owen, J. S.
    Melhem, M.
    D'Andrea, D.
    Darwish, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S54 - S55
  • [46] Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL)
    King, Jennifer K.
    Costenbader, Karen H.
    CLINICAL RHEUMATOLOGY, 2007, 26 (09) : 1491 - 1494
  • [47] Classification of Non-Hodgkin Lymphoma (NHL) in the Developing World:The International NHL Classification Project
    Perry, Anamarija
    Diebold, Jacques
    MacLennan, Kenneth
    Muller-Hermelink, H. Konrad
    Nathwani, Bharat N.
    Boilesen, Eugene
    Bast, Martin
    Armitage, James
    Weisenburger, Dennis D.
    MODERN PATHOLOGY, 2016, 29 : 368A - 368A
  • [48] Is there an optimal time for rituximab retreatment (ReRx) for patients with non-Hodgkin's lymphoma (NHL).
    Davis, TA
    Grillo-López, AJ
    McLaughlin, P
    White, CA
    Cairelli, S
    Alkuzweny, B
    Lee, D
    Levy, R
    BLOOD, 2000, 96 (11) : 733A - 733A
  • [49] Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin’s lymphoma (NHL)
    Jennifer K. King
    Karen H. Costenbader
    Clinical Rheumatology, 2007, 26 : 1491 - 1494
  • [50] Bexxar™ is an effective and well tolerated therapy in elderly patients with non-Hodgkin lymphoma (NHL).
    Ali, A
    Kaminski, M
    Gregory, SA
    Magnuson, D
    Wahl, R
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
12345